digoxin and Pneumonia--Viral

digoxin has been researched along with Pneumonia--Viral* in 2 studies

Other Studies

2 other study(ies) available for digoxin and Pneumonia--Viral

Article	Year
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7 Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells	2020
A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2. Signal transduction and targeted therapy, 2020, 10-03, Volume: 5, Issue:1 Topics: Animals; Antiviral Agents; Betacoronavirus; Biological Products; Bufanolides; Cardiac Glycosides; Cell Survival; Chlorocebus aethiops; Chloroquine; Coronavirus Infections; COVID-19; Digoxin; Gene Expression Regulation; High-Throughput Screening Assays; Host-Pathogen Interactions; Humans; Janus Kinases; Mitogen-Activated Protein Kinases; NF-E2-Related Factor 2; NF-kappa B; Pandemics; Phenanthrenes; Pneumonia, Viral; SARS-CoV-2; Signal Transduction; Sodium-Potassium-Exchanging ATPase; Vero Cells; Virus Replication	2020

Article

Year

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.

Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC

Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells

2020

A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2.

Signal transduction and targeted therapy, 2020, 10-03, Volume: 5, Issue:1

Topics: Animals; Antiviral Agents; Betacoronavirus; Biological Products; Bufanolides; Cardiac Glycosides; Cell Survival; Chlorocebus aethiops; Chloroquine; Coronavirus Infections; COVID-19; Digoxin; Gene Expression Regulation; High-Throughput Screening Assays; Host-Pathogen Interactions; Humans; Janus Kinases; Mitogen-Activated Protein Kinases; NF-E2-Related Factor 2; NF-kappa B; Pandemics; Phenanthrenes; Pneumonia, Viral; SARS-CoV-2; Signal Transduction; Sodium-Potassium-Exchanging ATPase; Vero Cells; Virus Replication

2020